This medicine can work for breast cancer, cancer of stomach.And most patients can control their cancer did not become bad for many years.(Sorry my English not enough for understand.If have translator I can tell more details.)

We use this kind peach's leaf made medicine and we already help many people recover from many different cancer.

Malnutrition is dreaded by patient, carer, and clinician and impacts both oncologic outcomes and patient quality of life. The question remains: do patients die of their cancer, the complications of their treatment, or associated malnutrition?

Integration of proactive PG-SGA (multilingual) with technology will help answer the critical questions above, improve quality of care, patient experience across the cancer continuum and oncologic outcomes and global interdisciplinary collaboration.

To integrate the gold standard of nutritional assessment, the validated Patient-Generated Subjective Global Assessment (PG-SGA), or its app, in oncology clinical trials, electronic medical records, and Big Data interfaces such as CancerLinQ -- to understand the impact of addressing (or failing to address) simple variables of weight loss, intake, symptoms/impediments and ECOG performance status on patient and oncologic outcomes.

How to turn basic cancer knowledge into useful interventions and durable products that can aid in detection, diagnosis, therapy and quality of life for survivors?

Engineering can bring solutions at scale and with a cost efficiency and innovation that can provide increased quality of care at lower cost. This can enable a wider benefit to patients, especially those undeserved by present approaches.

1. Engineering and technology based Cancer Center
2. Educate engineers in cancer applications
3. Multidisciplinary approaches to cancer problems that engage principles from physical sciences

Malnutrition is dreaded by patient, carer, and clinician and impacts both oncologic outcomes and patient quality of life. The question remains: do patients die of their cancer, the complications of their treatment, or associated malnutrition?

Integration of proactive PG-SGA (multilingual) with technology will help answer the critical questions above, improve quality of care, patient experience across the cancer continuum and oncologic outcomes and global interdisciplinary collaboration.

To integrate the gold standard of nutritional assessment, the validated Patient-Generated Subjective Global Assessment (PG-SGA), or its app, in oncology clinical trials, electronic medical records, and Big Data interfaces such as CancerLinQ -- to understand the impact of addressing (or failing to address) simple variables of weight loss, intake, symptoms/impediments and ECOG performance status on patient and oncologic outcomes.

The Moonshot will address perceived flaws in the cancer research enterprise. But the effects of these problems and of possible solutions on medical innovation are unknown because the NIH does not fund scientific research on cancer science policy.

This funded research will answer important questions like: Do precision cancer medicines tested using new clinical trial designs win approval more quickly? Do precompetitive public-private collaborations and data sharing accelerate innovation?

The NIH already has an Office of Science Policy with a small staff that pursues strategic initiatives on science policy, some of which may relate to cancer. Its grant funding on policy research generally relates to cancer care delivery, not cancer research. To accelerate our understanding of bottlenecks in cancer research, the NCI should create a cancer grant funding stream analogous to NSF's Science of Science and Innovation Policy program.

A means to easily activate mitochondria to induce apoptosis, to be combined w/other non-toxic methods & other treatments. Applications to treating Alzheimer's, Parkinson's & infectious diseases such as AIDS. Adds NIR to FIR/light methods of induction

Non-toxic means to wipe out cancer at will w/minimal side effects; possible means of immunization - also potentially curing Alzheimer's/Parkinson's & infectious diseases such as AIDS, particularly w/ultrasound. Most treatments would be very low cost.

Near-infrared light also reactivates mitochondria, which has applications to Alzheimer's/Parkinson's per NIMH study. Combined w/other methods of reactivation - DCA, quercetin, PQQ, FIR/light & other non-toxic treatments which augment each other. Bio-luminescent blood could carry NIR/FIR/light throughout body w/optogenetic on/off switch. Combining discussed methods could eradicate multiple diseases, or at least halt their progress.

Exposure of the heart to radiotherapy in the standard management of especially lung and breast cancers has been linked to increased long-term risk for cardiac events/morbidity. The etiology/mechanism for this damage remains unclear.

Data garnered from Cardiac MRI and biomarker testing could help guide treatment planning to reduce the long-term cardiac effects of radiotherapy. This could potentially affect the care of millions of patients worldwide annually.

Cardiac MRI has shown the capability to provide quantitative metrics of cardiac function and injury, while serum biomarkers remain some of the most effective and useful tests in the diagnosis and monitoring of heart damage/failure. These low-risk tests would be utilized before and after radiation therapy to elucidate the regions/extent of injury and to correlate these with radiotherapy dose to various substructures of the heart.

Childhood Leukemia and adult brain tumors from possible carcinogenic exposures to Extremely Low Frequency EMF radiation in buildings

The science based evidence shows that such exposures are possible carcinogenic exposures therefore mitigating them will reduce risks at no to low cost- childhood leukemia is the #1 cancer for children addressing it is worthwhile!

Work to provide building facility training to measure and repair all ELF EMF exposure levels at or above 2 mG in all school, residential and commercial building new construction and modernizations from NET CRRENTS that are mis-wiring NEC code violations.

Despite decades of research, the full incidence of CIPN is poorly defined. New research suggests that even less severe CIPN can impact quality of life and daily function, but open-access to this data is a problem.

An open-platform dataset would shed light on the true incidence of CIPN. More complete data would help us understand the impact of mild to moderate CIPN on areas such as survivors' occupational funcitonal and quality of life.

Create an open-platform hub for the sharing clinical trial data on CIPN that includes all levels (grades I-IV) of neuropathy. Where possible, this dataset should include relevant quality of life, occupational, and functional characteristics about patients.

Technologies that can detect early signs of CIPN (including the most debilitating CIPN) are urgently needed. To be cost-effective and have high-uptake, this research needs to include the nurses that will perform the majority of these tests.

In the absence of treatments for CIPN, early detection is critical to minimizing long-term morbidity in survivors. Harnessing nurses' expertise will be vital to identifying viable early detection that are likely to be used in routine practice.

Convene an expert panel of researchers, nurses, physicians, pharmacists, neurologists and engineers to (1) identify promising early detection methods for CIPN; (2) get input from nurses on the characteristics that would be needed to make these potential screening tools useful in practice, (3) disseminate these findings, (4) use these findings to fast-track development/testing of these tools.

Inoperable malignant tumors are difficult to manage and their fatal agenda kills people and companion animals every day.
We need help with 5 items in the attachment below to accelerate the use of Radiogel Y-90 Device.
See attachment!

Radiogel reduces tumors without surgery. There are no adverse events for patients to endure while tumors undergo shrinkage and a second treatment can be given if needed. Radiogel will spare cancer patients with inoperable tumors. See attachment

Radiogel is a novel combination of Yttrium-90 (Y-90) isotope and a polymer, which can be injected into tumors using a fine needle. The cancer patient's body temperature initiates a phase transfer that entraps the isotope within the tumor. Y-90 is a beta emitter with a short half life of 2.7 days. Radiogel Y-90 device provides a new, practical and significantly less expensive, more effective resorbable localized therapy.
See attachment

Virtual reality exposes the eyes and brain to close range microwave radiation. Phones were never tested in such positions. Research shows the eyes are most vulnerable to this radiation. Effects could include increased cancer as well as blindness.

Schools need state of the art 21st century technology but we need it to be safe for children. A transmitting smartphone to the eyes of children in classrooms with virtual reality is not healthy.
Children need safe/healthy technology tools.

Before schools roll out such technology, research should be done to understand the effects of this radiation on a child's developing eye and brain.

Furthermore, there is no research that considers the current electromagnetic radiation environment in schools. Between the virtual reality systems and the cell phones/Wi-Fi, the exposures are unprecedented. Exposure should be reduced until studies are done to characterize the risk and environment.

From its programs it seems as if the NCI believes that technology, data, data-sharing and data analytics suffice to bring new insights. But enamored with technology & data, we have abnegated theory which is indispensable to give meaning to data.

Theory based on first principles (not 'modeling') is cheap and by exposing the formal limits of cell killing could even improve therapy. Theory could catalyze entire fields of research, bringing meaning to the data that we collect in blind frenzy.

Without theory in biology we would still collect specimen and build taxonomy but not understand evolution. In cancer research we eschew theory. The relentless progression of tumors demands an unifying theory. (Modeling is not theory, just mathematized phenomenology). The NCI needs the courage to promote theory without crying 'experimental validation' in the same breath. This is simple. And theory is inexpensive and can be invaluable.

Lab rodents do not represent humans - varied genetics, age, and co-morbidities, often failing to predict treatment success and costing time and money via misdirection. Rare/pediatric cancers lack population numbers for trials.

Case study: recent work in a new brain cancer drug suggests savings of 5 years and millions of dollars since biodistribution, safety, starting dose, and patient selection were all de-risked in dogs with brain tumors in the course of a single year.

Enroll more companion animals in clinical trials with cancers that parallel human disease, invest in the sequencing of spontaneous animal cancers to comprehend the similarities and differences - already many identical pathways have been identified. Some rare/pediatric cancers occur plentifully in the dog population and offer resource for study options.

Cell towers may cause cancer for people who live within 400 meters of them.

This will reduce the cancer clusters that occur near cell towers. This will result in healthier people and reduce the impact that cancer has on the health system and the people who are impacted by the diagnosis.

To stop cell towers from being built near residential areas, schools, and hospitals.